Want to see IN:APLLTD full AI Analyst Report?

Alembic Pharmaceuticals Limited (APLLTD) Price & Analysis

2 Followers

APLLTD Stock Chart & Stats

₹814.00

₹16.85(2.11%)

At close: Jul 27 4:00 PM EDT

₹814.00

₹16.85(2.11%)

Day’s Range― - ―

52-Week Range₹635.30 - ₹998.00

Previous CloseN/A

Volume50.27K

Average Volume (3M)22.74K

Market Cap

₹165.96B

Enterprise Value₹142.31K

Total Cash (Recent Filing)₹1.96B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)23.4

Beta1.02

Next Earnings

Nov 10, 2026

EPS Estimate

10.05

Next Dividend Ex-DateN/A

Dividend Yield1.45%

Share Statistics

EPS (TTM)35.27

Shares Outstanding196,563,130

10 Day Avg. Volume34,714

30 Day Avg. Volume22,742

Financial Highlights & Ratios

PEG Ratio1.23

Price to Book (P/B)2.30

Price to Sales (P/S)1.77

P/FCF Ratio50.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)37.69

Revenue Forecast (FY)₹84.17B

Bulls Say, Bears Say

Bulls Say

Steady Revenue GrowthSustained revenue expansion indicates ongoing demand across Alembic's pharmaceutical portfolio. Continued growth in formulations and APIs can support scale, market reach, and operating resilience over the next several quarters.

Conservative Balance SheetLow leverage and a growing equity base provide financial flexibility for product development, manufacturing investment, and regulatory needs. This strengthens resilience if pharmaceutical pricing or commercialization conditions weaken.

Diversified Pharmaceutical ModelExposure to branded medicines, generics, APIs, and multiple geographies diversifies revenue sources. This broad platform can reduce dependence on any single product, market, or customer and support durable commercial opportunities.

Bears Say

Volatile Cash GenerationThe sharp year-to-year swing in operating and free cash flow signals working-capital and execution risk. Even with the 2026 rebound, inconsistent conversion of earnings into cash can constrain investment flexibility and financial predictability.

Margin CompressionProfitability has normalized below earlier peak levels, showing that earnings power can fluctuate. Persistent pricing pressure, product mix changes, or development costs could limit the ability of revenue growth to translate into profit growth.

Moderating Growth PaceAlthough the multi-year revenue trend is positive, the latest annual slowdown suggests growth may not remain consistently strong. A moderating pace could make fixed-cost absorption and the funding of future product launches more challenging.

Alembic Pharmaceuticals Limited News

Alembic Pharmaceuticals Schedules One-on-One Meetings With Investors and Analysts

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) just unveiled an update. Alembic Pharmaceuticals has scheduled a series of one-to-one...

7d ago

Alembic Pharma Schedules One-to-One Meetings With Key Investors and Analysts

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals Limited has announced that its management...

7d ago

Alembic Pharmaceuticals Sets August 5 Virtual AGM, Announces E-Voting and Dividend Record Date

An announcement from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has notified exchanges and...

2M ago

Alembic Pharma Schedules One-on-One Meets With Key Institutional Investors

An announcement from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has disclosed that its...

3M ago

Alembic Pharmaceuticals Plans One-on-One Meets With Key Institutional Investors

An update from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has scheduled a series...

3M ago

Alembic Pharmaceuticals Lines Up One-on-One Meetings With Key Institutional Investors

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals has scheduled one-on-one investor...

3M ago

Alembic Pharma Sets Virtual AGM, Record Date and Updates Dividend, KYC, and TDS Rules

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals has announced that its 16th Annual...

3M ago

Alembic Pharma Takes 45% Stake in New Canadian Drug Venture

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has shared an announcement. Alembic Pharmaceuticals Limited has signed a shareholders’ agreement...

3M ago

Alembic Pharmaceuticals Announces Death of Senior Delhi-Based Director

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an update. Alembic Pharmaceuticals has announced the death of Mr....

4M ago

Alembic Pharma Wins USFDA Nod for Generic Multiple Sclerosis Drug

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an update. Alembic Pharmaceuticals has received final approval from the...

4M ago

APLLTD FAQ

What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?

Alembic Pharmaceuticals Limited lowest stock price was ₹635.30 and its highest was ₹998.00 in the past 12 months.

What is Alembic Pharmaceuticals Limited’s market cap?

Alembic Pharmaceuticals Limited’s market cap is ₹165.96B.

When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?

Alembic Pharmaceuticals Limited’s upcoming earnings report date is Nov 10, 2026 which is in 68 days.

How were Alembic Pharmaceuticals Limited’s earnings last quarter?

Alembic Pharmaceuticals Limited released its earnings results on Aug 04, 2026. The company reported ₹8.8 earnings per share for the quarter, beating the consensus estimate of ₹7.788 by ₹1.012.

Is Alembic Pharmaceuticals Limited overvalued?

According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alembic Pharmaceuticals Limited pay dividends?

Alembic Pharmaceuticals Limited pays a Annually dividend of ₹12 which represents an annual dividend yield of 1.45%. See more information on Alembic Pharmaceuticals Limited dividends here

What is Alembic Pharmaceuticals Limited’s EPS estimate?

Alembic Pharmaceuticals Limited’s EPS estimate is 10.05.

How many shares outstanding does Alembic Pharmaceuticals Limited have?

Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.

What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?

Alembic Pharmaceuticals Limited reported an EPS of ₹8.8 in its last earnings report, beating expectations of ₹7.788. Following the earnings report the stock price went up 0.434%.

Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:APLLTD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and a wide array of formulations. The company provides both proprietary (branded) and generic medications, addressing numerous therapeutic needs such as cardiovascular health, women's health, gastrointestinal issues, eye and skin conditions, kidney/urinary tract disorders, orthopedic ailments, anti-infective treatments, remedies for cold and cough, and anti-diabetic management. Furthermore, the company engages in the export of its diverse product portfolio. Founded in 1907, Alembic Pharmaceuticals Limited maintains its main office in Vadodara, India.